PetCaseFinder

Peer-reviewed veterinary case report

Higher IGF-1 receptor levels linked to worse survival in dogs

By Maniscalco, Lorella et al.·Published in Veterinary journal (London, England : 1997)·2015·Department of Veterinary Sciences, Italy·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Increased expression of insulin-like growth factor-1 receptor is correlated with worse survival in canine appendicular osteosarcoma.

Species:
dog
OsteosarcomaMovement & jointsDogs

Plain-English summary

A study found that dogs with osteosarcoma (a type of bone cancer) often have higher levels of a protein called IGF-1R, which is linked to worse survival rates. In the research, 34 dogs were examined, and it was noted that those with more IGF-1R had a significantly shorter lifespan. The researchers also tested a treatment that blocked IGF-1R, which showed promise in reducing cancer cell activity and promoting cell death. This suggests that targeting IGF-1R could be a potential treatment option for dogs with this aggressive cancer.

People also search for: dog osteosarcoma treatment · IGF-1R in dogs · canine bone cancer prognosis

Abstract

Insulin-like growth factor 1 receptor (IGF-1R) is a cell membrane receptor widely expressed in tissues and involved in different cancers in humans. IGF-1R expression in human osteosarcoma has been associated with the development of tumour metastasis and with prognosis, and represents an attractive therapeutic target. The goal of this study was to investigate the expression of IGF-1R in canine osteosarcoma tissues and cell lines and assess its role and prognostic value. Samples from 34 dogs were examined by immunohistochemistry for IGF-1R expression. IGF-1R/AKT/MAPK signalling was evaluated by western blot and quantitative polymerase chain reaction in the cell lines. In addition, the in vitro inhibition of IGF-1R with pycropodophillin (PPP) was used to evaluate molecular and biological effects. Immunohistochemical data showed that IGF-1R was expressed in 71% of the analysed osteosarcoma samples and that dogs with higher levels of IGF-IR expression (47% of cases) had decreased survival (P&#x2009;<&#x2009;0.05) when compared to dogs with lower IGF-IR expression. Molecular studies demonstrated that in canine osteosarcoma IGF-IR is activated by IGF-1 mostly in a paracrine or endocrine (rather than autocrine) manner, leading to activation of AKT/MAPK signalling. PPP caused p-IGF-1R dephosphorylation with partial blocking of p-MAPK and p-AKT, as well as apoptosis. It was concluded that IGF-1R is expressed and plays a role in canine osteosarcoma and that its expression is correlated with a poor prognosis. As in humans, IGF-1R may represent a good therapeutic target and a prognostic factor for canine osteosarcoma.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/25257352/